Clexio Biosciences Is A Clinical Stage Pharmaceutical Company Focused On Developing Therapies For Neurological And Psychiatric Conditionsfounded In 2018The Company Is Supported By Strong Financial Backing And A Global Network Of Partnersclexio Aims To Create Innovative Solutions By Aligning Patient Needs With Validated Mechanisms Of Action And Technology The Company Specializes In End To End Drug Developmentfrom Early Innovation To Clinical Trials And Regulatory Approvalsclexio S Experienced Multidisciplinary Team Is Dedicated To Advancing New Therapeutic Modalitiestheir Pipeline Includes Candidates For Major Depressive Disorderschizophreniabipolar Depressionchronic Pruritusneuropathic Paincluster Headacheand Parkinsonae S Diseasenotablytheir Lead Candidatecle 100Is Currently In Phase 2 Studies For Major Depressive Disorderclexio Biosciences Is Committed To Addressing Unmet Needs In The Cns Therapeutic Space
United States
